GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shattuck Labs Inc (NAS:STTK) » Definitions » Beneish M-Score

Shattuck Labs (Shattuck Labs) Beneish M-Score : -0.35 (As of May. 08, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Shattuck Labs Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.35 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Shattuck Labs's Beneish M-Score or its related term are showing as below:

STTK' s Beneish M-Score Range Over the Past 10 Years
Min: -10.67   Med: -5.62   Max: 24.33
Current: -0.35

During the past 6 years, the highest Beneish M-Score of Shattuck Labs was 24.33. The lowest was -10.67. And the median was -5.62.


Shattuck Labs Beneish M-Score Historical Data

The historical data trend for Shattuck Labs's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shattuck Labs Beneish M-Score Chart

Shattuck Labs Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - -0.50 -8.19 -1.07

Shattuck Labs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.67 -10.22 -7.24 -1.07 -0.35

Competitive Comparison of Shattuck Labs's Beneish M-Score

For the Biotechnology subindustry, Shattuck Labs's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shattuck Labs's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shattuck Labs's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Shattuck Labs's Beneish M-Score falls into.



Shattuck Labs Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Shattuck Labs for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 1+0.404 * 0.9987+0.892 * 3.8293+0.115 * 0.7416
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.2364+4.679 * -0.100748-0.327 * 1.0625
=-0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $0.00 Mil.
Revenue was 1.115 + 0.714 + 0.686 + 0.2 = $2.72 Mil.
Gross Profit was 1.115 + 0.714 + 0.686 + 0.2 = $2.72 Mil.
Total Current Assets was $131.08 Mil.
Total Assets was $146.34 Mil.
Property, Plant and Equipment(Net PPE) was $12.83 Mil.
Depreciation, Depletion and Amortization(DDA) was $4.00 Mil.
Selling, General, & Admin. Expense(SGA) was $19.15 Mil.
Total Current Liabilities was $14.33 Mil.
Long-Term Debt & Capital Lease Obligation was $3.19 Mil.
Net Income was -18.504 + -17.687 + -27.541 + -21.346 = $-85.08 Mil.
Non Operating Income was 1.54 + -3.405 + 1.057 + 1.401 = $0.59 Mil.
Cash Flow from Operations was -16.161 + -19.419 + -16.732 + -18.616 = $-70.93 Mil.
Total Receivables was $0.00 Mil.
Revenue was 0.057 + 0.39 + 0.212 + 0.05 = $0.71 Mil.
Gross Profit was 0.057 + 0.39 + 0.212 + 0.05 = $0.71 Mil.
Total Current Assets was $157.84 Mil.
Total Assets was $177.68 Mil.
Property, Plant and Equipment(Net PPE) was $16.89 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.62 Mil.
Selling, General, & Admin. Expense(SGA) was $21.15 Mil.
Total Current Liabilities was $16.01 Mil.
Long-Term Debt & Capital Lease Obligation was $4.01 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 2.715) / (0 / 0.709)
=0 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.709 / 0.709) / (2.715 / 2.715)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (131.076 + 12.83) / 146.335) / (1 - (157.837 + 16.887) / 177.677)
=0.016599 / 0.01662
=0.9987

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2.715 / 0.709
=3.8293

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(3.615 / (3.615 + 16.887)) / (4.002 / (4.002 + 12.83))
=0.176324 / 0.237761
=0.7416

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(19.148 / 2.715) / (21.154 / 0.709)
=7.05267 / 29.836389
=0.2364

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((3.193 + 14.329) / 146.335) / ((4.014 + 16.009) / 177.677)
=0.119739 / 0.112693
=1.0625

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-85.078 - 0.593 - -70.928) / 146.335
=-0.100748

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Shattuck Labs has a M-score of -0.35 signals that the company is likely to be a manipulator.


Shattuck Labs Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Shattuck Labs's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Shattuck Labs (Shattuck Labs) Business Description

Traded in Other Exchanges
N/A
Address
500 W. 5th Street, Suite 1200, Austin, TX, USA, 78701
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
Executives
Andrew R Neill officer: See Remarks 1018 W 11TH STREET, SUITE 100, AUSTIN TX 78703
Stephen Stout officer: See Remarks C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701
George Golumbeski director C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Abhinav A. Shukla officer: Chief Technical Officer 500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701
Carrie Brownstein director 500 W. 5TH ST., SUITE 1200, AUSTIN TX 78701
Erin Ator Thomson officer: General Counsel 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Josiah Hornblower director, 10 percent owner, officer: Chairman 3317 BOWMAN AVE, AUSTIN TX 78703
Taylor Schreiber director, officer: Chief Executive Officer 100 EUROPA DRIVE, CHAPEL HILL NC 27517
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Helen M Boudreau director 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Neil W Gibson director C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Tyler Brous director 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Casi Deyoung officer: Chief Business Officer C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744
Arundathy N. Pandite officer: Chief Medical Officer 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Victor Stone director 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703

Shattuck Labs (Shattuck Labs) Headlines

From GuruFocus

Shattuck Labs Announces Participation in Upcoming November Conferences

By Value_Insider Value_Insider 11-03-2022